Global Generative AI In Clinical Trials Market Size Likely to Grow at a CAGR of 9.63% By 2035

Market Size and Growth

The global Generative AI in Clinical Trials market size was estimated at USD 0.81 billion in 2026 and is projected to reach USD 1.86 billion by 2035 with a compound annual growth rate (CAGR) of 9.63% between the forecast period (2026-2035).

Global Generative AI in clinical trails Market Revenue and Trends

The Generative AI in Clinical Trials market encompasses the adoption of generative artificial intelligence technologies, large language models (LLMs), multimodal AI, machine learning platforms, natural language processing (NLP), synthetic data generation tools, AI-powered clinical trial management systems, and predictive analytics solutions to optimize the planning, execution, and management of clinical trials.

These technologies are transforming pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic research institutes, hospitals, and regulatory stakeholders by enabling protocol design optimization, patient recruitment, eligibility matching, synthetic control arm generation, clinical document automation, adverse event analysis, site selection, and real-time trial monitoring.

The global Generative AI in Clinical Trials market is experiencing significant growth, driven by increasing clinical trial complexity, rising pharmaceutical R&D investments, growing demand to reduce drug development timelines and costs, expanding adoption of AI-enabled drug development platforms, and increasing use of generative AI to improve operational efficiency, patient engagement, and regulatory documentation throughout the clinical research.

What are the Factors That Have a Significant Contribution to the Growth of the global Generative AI in clinical trails market?

Generative AI technologies have been rapidly integrated into the clinical trial landscape due to the growing complexity, length, and expense of these trials. Generative AI is being adopted more by pharmaceutical companies, biotechnology firms and CROs to optimize protocol design, identify patient eligibility, automate patient recruitment, forecast patient enrollment, create synthetic patient data, and streamline clinical documentation.

The rising number of chronic diseases, rare diseases, oncology research and personalized medicine are driving an increasing number and complexity of clinical trials around the world, which is driving up the demand for AI solutions to optimize clinical trials. Furthermore, increasing the need to decrease the number of trials that fail, increase patient retention, increase data quality and reduce drug development timelines is driving organizations to invest in generative AI platforms that can help them operate faster and make evidence-based decisions.

The rising level of R&D spending and the growing pipeline of biologics, cell and gene therapies, and precision medicines is likely to continue to drive market growth.

The pace of innovation in the field of generative AI, large language models (LLMs), multimodal AI, natural language processing, synthetic data generation, and predictive analytics is changing the nature of clinical trials. Today, AI can optimize trial protocols, synthesize scientific literature automate regulatory documentation, analyze EHRs, track patient safety signals and provide real-time decision making throughout the trial.

Integration with cloud computing, digital health platforms, wearable devices, remote patient monitoring systems, and decentralized clinical trials further enhances AI-driven clinical research capabilities. In addition, the generative AI in clinical trials market will see significant growth opportunities over the forecast period due to the growing investments made by pharmaceutical companies, CROs, healthcare technology providers, and research institutions in AI-driven clinical development, digital trial infrastructure, and AI solutions that comply with regulatory guidelines.

Opportunities Impact Analysis

Challenges Impact Analysis

Segment Insight

By Deployment Mode

Cloud has emerged as the leader because it is scalable, high-performance computing, and can cope with the complexity of AI model development, deployment, and sharing between geographically distributed clinical trial teams. By leveraging cloud-based platforms, pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) can effectively integrate generative AI into their procedures, including electronic health records (EHRs), clinical trial management systems (CTMS), and electronic data capture (EDC) platforms, thereby cutting infrastructure costs and streamlining the progression of clinical trials. Cloud adoption is growing in clinical research throughout the world, bolstered by the flexibility of Software-as-a-Service (SaaS) models and secure cloud environments.

By Technology

Large Language Models (LLMs) are the big winners because they provide the automation of protocol development, medical writing, patient eligibility screening, regulatory documentation, and clinical knowledge extraction. They can extract and derive meaning from large, complex sets of structured and unstructured clinical data, which helps streamline research processes and lowers manual efforts. The use of AI in the healthcare sector continues to grow, with continuous progress in AI models tailored for medical research, retrieval-augmented generation (RAG), and multimodal AI further enhancing their role in clinical trials across various stages.

By Clinical Trial Phase

The biggest share is assigned to phase III, because the high complexity and size of the patient population and significant operational cost of the late-stage clinical trials increase the size of the market. The following are examples of how generative AI can facilitate Phase III studies: Generative AI can be used to optimize patient recruitment and predict enrollment trends, automate clinical documentation, monitor trial performance, detect safety signals, and streamline regulatory submissions. Pharma companies are increasingly investing in making trials more successful, speeding up regulatory approval and shorten trial timelines, which is why Phase III remains the most prevalent use case for generative AI solutions.

Regional Insights

The Generative AI in Clinical Trials market is expected to witness high adoption of AI technologies, strong clinical research infrastructures, and substantial investments in R&D, leading to the presence of the top AI technology providers and CROs in North America, which also boasts a well-established pharmaceutical and biotechnology ecosystem. The market leadership of the region is further bolstered by supportive regulatory initiatives, digital transformation, and extensive adoption of cloud-based clinical trial platforms.

Asia Pacific is projected to see the highest growth rate over the forecast period, owing to the growing pharmaceutical manufacturing sector, growing clinical trial activities, rising investments in AI drug development, increasing adoption of digital health technologies, and supportive government initiatives that encourage and promote healthcare innovation. Generative AI solutions for clinical trials have seen a surge of potential growth opportunities, with countries like China, India, Japan, South Korea, Singapore, and Australia investing heavily in building AI-driven clinical research infrastructure.

Report Scope

Recent Developments

• In June 2025 – IQVIA improved its AI powered medical research ability as the business improved the generative AI features of its medical trial style, patient enrolment, and also study operations software programs to help pharma business as well as CROs speed up medical trial duration, increase protocol efficiency, as well as optimize client enlistment rates.

List of the prominent players in the generative AI in the clinical trials market:

• IQVIA Holdings Inc.

• Medidata Solutions (Dassault Systèmes)

• Oracle Health Sciences (Oracle Corporation)

• Veeva Systems Inc.

• Microsoft Corporation

• Google LLC (Google Cloud)

• Amazon Web Services (AWS)

• NVIDIA Corporation

• Tempus AI Inc.

• Unlearn AI Inc.

• Saama Technologies LLC

• Insilico Medicine

• PathAI Inc.

• Owkin Inc.

• ConcertAI LLC

• Others

The Generative AI In Clinical Trials Market is segmented as follows:

By Deployment Mode

• Cloud

• On-Premises

• Hybrid

By Technology

• Generative AI

• Large Language Models (LLMs)

• Natural Language Processing (NLP)

• Machine Learning & Deep Learning

• Predictive Analytics

• Computer Vision

• Retrieval-Augmented Generation (RAG)

• Knowledge Graphs

• Multimodal AI

By Clinical Trial Phase

• Phase I

• Phase II

• Phase III

• Phase IV

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America